Synthesis and preliminary evaluation of (S)-(2-[18F]Fluoro-4,5-dihydroxyphenyl)-2-methyl L-alanine, (S)-[18F]-FMEDOPA, a potentially improved imaging agent for the presynaptic dopaminergic nervous system

Nuclear Medicine and Biology

Volumn 23, Issue 7, 1996, Pages 857-865

  Yost, Yul ^a   Conway, Terry ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

(2 18F fluoro 4,5 dihydroxyphenyl) 2 methyl L alanine; Dopaminergic nervous system; PET imaging agent; 18F FDOPA; 18F FMEDOPA

Indexed keywords

ALANINE DERIVATIVE; FLUORINE 18;

ANIMAL EXPERIMENT; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG DISTRIBUTION; DRUG SYNTHESIS; ISOTOPE LABELING; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; RAT; REVIEW;

EID: 0030271758     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(96)00056-X     Document Type: Article

References (54)

1. 1. Ames M. M., Melmon K. L. and Castagnoli N. (1977) Stereochemical course in vivo of alpha-methyldopa decarboxylation in rat brains. Biochem. Pharm. 26, 1757-1762.
2. 14C-labeled α-methyldopa in normal and hypertensive human subjects. Biochem J. 129, 1-10.
3. 3. Barrio J. R., Huang S-C. and Phelps M. E. (1988) In vivo assessment of neurotransmitter biochemistry in humans. Annu. Rev. Pharmacol. Toxicol. 28, 213-230.
4. 4. Bhatt M. H., Snow B. J., Martin W. R. W., Pate B. D., Ruth T. J. and Calne D. B. (1991) Positron emission tomography suggests that the rate of progression of idiopathic Parkinsonism is slow. Ann Neurol. 29, 673-677.
5. 18F]-DOPA uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann. Neurol. 28, 547-555.
6. 6. Brooks, D. J., Ibanez V., Playford E. D. et al. (1991) Presynaptic and postsynaptic striatal dopaminergic function in neuroacanthocytosis: A positron emission tomographic study. Ann. Neurol. 30, 166-171.
7. 7. Brooks D. J. (1993) Functional imaging in relation to parkinson syndromes. J. Neurol. Sci. 115, 1-17.
8. 18F]fluoro-L-dopa. J. Label. Compd. Radiopharm. 26, 228-229.
9. 18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521. Biochem. Pharmacol. 36, 2527-2531.
10. 10. DeJesus O. T., Mukherjee J. and Appelmann E. H. (1989a) Synthesis of o-and m-tyrosine analogs as potential tracers for CNS dopamine. J. Label. Compd. Radiopharm. 26, 133-134.
11. 11. DeJesus O. T., Sunderland J. J., Chen C-A., Nickles, R. J., Mukherjee J. and Appelman E. H. (1989b) Synthesis of radiofluorinated M-tyrosine analogs as potential L-DOPA PET tracers. J. Nucl. Med. 30, 930-937.
12. 18F]Fluoro-MDL (72394, a potentially trappable tracer for presynaptic dopamine neurons. J. Nucl. Med. 30, 902.
13. 18F-labeled α-fluoromethyl-p-tyrosine, a tyrosine hydroxylase-activated decarboxylase suicide inhibitor with potential as an imaging agent for dopamine nerve terminals. J. Label. Compd. Radiopharm. 32, 260-261.
14. 14. De Jong W. and Van Giersbergen P. (1990) Alpha-methyldopa. In: Enzymes as Targets for Drug Design, pp. 31-44. Academic Press, NY.
15. 18F-DOPA. J. Nucl. Med. 32, 1408-1413.
16. 14C unter besonderer Beruecksichtigung der optischen Isomeren. Z. Naturforsch. B: Anorg. Chem. Org. Chem. 22, 70-84.
17. 18F-fluoro-dopa positron emission tomographic studies. Mov. Disord. 5, 203-213.
18. 18F-DOPA uptake: Absence of an aging effect. J. Cereb. Blood Flow Metab. 13, 881-888.
19. 18F]Fluoro-L-dopa for the in vivo study of intracerebral dopamine. Int. J. Radiat. Appl. Instrum. Part A, 37, 669-676.
20. 20. Firnau G., Chirakal R., Nahmias C. and Garnett E. S. (1991) Tracers for the investigation of cerebral presynaptic dopaminergic function with positron emission tomography. In: Frontiers in Nuclear Medicine: In Vivo Imaging of Neurotransmitter Function in Brain, Heart and Tumors (Edited by Kuhl D.), pp. 67-92. American College of Nuclear Physics, Washington, DC.
21. 21. Freed C. R., Quintero E. and Murphy R. C. (1978) Hypotension and hypothalamic amine metabolism after long-term α-methyldopa infusions. Life Sci. 23, 313-322.
22. 22. Freed C. R., Breeze R. E., Rosenberg N. L., Schneck S. A., Wells T. H., Barrett J. N., Grafton S. T., Huang S C., Eidelberg D. and Rottenberg D. A. (1990) Transplantation of human fetal cells for Parkinson's disease. Arch Neurol. 47, 505-512.
23. 23. Furlano D. C. and Kirk K. (1986) An improved synthesis of 4-fluoroveratrole: Efficient route to 6-fluoroveratraldehyde and 6-fluoro-DL-DOPA. J. Org. Chem. 51, 4073-4075.
24. 24. Georgiou N., Bradshaw J. L., Phillips J. G., Bradshaw J. A. and Chiu E. (1995) Advance information and movement sequencing in Gilles de la Tourette's syndrome. J. Neurol. Neurosurg. Psychiatry 58, 184-191.
25. 25. Gildersleeve D. L., Van Dort M. E., Rosenspite K. C., Toorongian S., Sherman P. S. and Wieland D. M. (1989) Synthesis of [H-3]-L-m-tyrosine, [H3]-U-methyl-L-m-tyrosine, and 4-[F-18]-fluoro-D, L-m-tyrosine as potential protracers for dopamine neuron mapping. J. Nucl. Med. 30, 752-762.
26. 26. Grierson J. R. and Adam M. J. (1986) A practical preparative scale synthesis of D/L-6-fluorodopa. J. Label Compd. Radiopharm. 23, 1019-1028.
27. 27. Guttman M., Leger G., Reches A., Evans A. et al. (1993) Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov. Disord. 8, 298-304.
28. 18F]fluoro-DOPA metabolism in living human brain: A comparison of six analytical methods. J Cereb. Blood Flow Metab. 13, 57-69.
29. 29. Huang S. C., Barrio J. R., Hoffman J. M., Mahoney D. K., Hawk, T. C., Melaga W. P., Luxen A., Grafton S., Mazziotta J. C. and Phelps M. E. (1989) A compartmental model for 6-[F-18]fluoro-L dopa kinetics in cerebral tissues. J. Nucl. Med. 30, 735-745.
30. 30. Kirk K. and Creveling C. R. (1984) The chemistry and biology of ring-fluorinated biogenic amines. Med. Res. Rev. 4, 189-220.
31. 31. Lacan G., Saryamurthy N. and Barrio J. R. (1995) Fluorination of (E)-b-(Fluoromethylene-m-Tyrosine: Regioselective synthesis of 4-fluoro-(E)-b-(Fluoromethylene)-m-Tyrosine. J. Org. Chem. 60, 227-234.
32. 32. Leenders K. L., Palmer A. J., and Quinn N. (1986) Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J. Neurol. Neurosurg. Psychiatry 49, 853-860.
33. 33. Leenders K. L., Frackowiak R. S. J. and Lees A. J. (1988) Steele-Richardson-Olszewski syndrome: Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. Brain 111, 615-630.
34. 34. Lemaire C. P., Amhaut D., Plenevaux A. and Comar D. (1994) Enantioselective synthesis of 6-[Fluorine-18]Fluoro-L-DOPA from no-carrier-added fluorine-18 Fluoride. J. Nucl. Med. 35, 1996-2002.
35. 35. Lindvall O., Brundin P., Widner H., Rehndrona S., Freedman R., Hoffer B., Frakkowiack R., Leenders K. L., Sawle G., Rothwell J. C., Marsden C. D. and Bjorklund A. (1990) Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 247, 574-577.
36. 36. Luxen A., Monclus M., Hendrickx P.-Y. and Masson C. (1993) Synthesis and HPLC separation of 6-Fluoro-L-DOPA metabolites. Bull. Soc. Chim. Belg. 102, 217-225.
37. 18F]fluorodopa and in-vivo metabolites via regioselective fluorodemercuration. J. Nucl. Med. 28, 624-631.
38. 38. Luxen A. and Barrio J. (1988) Fluorination of substituted veratroles via regioselective mercuration. Tet. Lett. 29, 1501-1504.
39. 18F]Fluorodopa. J. Label. Compd. 23, 1066.
40. 18F]Fluoro-L-m-tyrosine: An L-3, 4-dihydroxyphenylalanine analog for probing presynaptic dopaminergic function with positron emission tomography. J. Neurochem. 53, 311-314.
41. 41. Merck Patent: European patent application number 80106408.0, 06.05.81.
42. 18]Fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys. Brain Res. 626, 1-13.
43. 43. Parulkar A., Burger A. and Aures D. (1966). Some nuclear-substituted derivatives of α-methyldopa. J. Med. Chem. 9, 738-741.
44. 44. Pate B. D., Kawamata T., Yamada T., McGeer E. G. et al. (1993) Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann. Neurol. 34, 331-338.
45. 45. Sawle G. V., Colebatch J. G., Shah A., Brooks D. J., Marsden C. D. and Frackowiak R. S. J. (1990) Striatal function in normal aging: Implications for Parkinson's disease. Ann. Neurol. 28, 700-804.
46. 46. Sawle G. V., Brooks D. J., Marsden C. D. and Frackowiak R. S. J. (1991) Corticobasal degeneration: A unique pattern of regional cortical oxygen metabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain 114, 541-556.
47. 47. Sawle G. V. (1992a) The rate of progression of Parkinson's disease. Ann. Neurol. 31, 229.
48. 18F]Dopa PET studies in an Irish kindred. Ann. Neurol. 32, 609-617.
49. 49. Sawle G. V. and Myers R. (1993) The role of positron emission tomography in the assessment of human neurotransplantation. Trends Neurosci. 16, 172-176.
50. 50. Sawle G. V. (1995). Imaging the head: Functional imaging. J. Neurol. Neurosurg. Psychiatry 58, 132-144.
51. 51. Schrecker A. W. and Hartwell J. L. (1957) The absolute configuration of lignans. J. Am. Chem. Soc. 79, 3827-3831.
52. 52. Sedvall G., Farde L., Persson A. and Wiesel F-A. (1986) Imaging of neurotransmitter receptors in the living human brain. Arch. Gen. Psychiatry 43, 995-1005.
53. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann. Neurol. 34, 324-330.
54. 54. Tyrrell P. J., Sawle G. V., Bloomfield P. M. et al. (1990) Clinical and PET studies in the extrapyramidal syndrome of dementia of the Alzheimer type. Arch. Neurol. 47, 1318-1323.